Acquisition will strengthen the mRNA-based cancer immunotherapy candidates, marking BioNTech’s milestone in its oncology strategy. Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. All-stock acquisition has potential to create value for both companies’ shareholders given their complementary capabilities, focus on mRNA, and shared vision.

Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger RNA – a prerequisite for protein synthesis in the cell. The poorly characterized factors are crucial to ensuring that the molecular machine responsible for splicing is working correctly. A research team has deciphered how the two cellular quality inspectors work.

With the goal of creating living cells from non-living components, scientists in the field of synthetic biology work with RNA origami. This tool uses RNA biomolecule to fold new building blocks, making protein synthesis superfluous. In pursuit of the artificial cell, a research team has cleared a crucial hurdle. Using the new RNA origami technique, they succeeded in producing nanotubes that fold into cytoskeleton-like structures.

The spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA. Splicing is a basic requirement for producing proteins. Researchers at the Heidelberg University Biochemistry Center (BZH) have succeeded for the first time in depicting a faultily “blocked” spliceosome at high resolution and reconstructing how it is recognized and eliminated in the cell.

Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene activity using methyl groups is responsible.

They are underestimated genetic control elements: it is known that changes in the genome can trigger diabetes. But now researchers at the University Hospital Ulm and the INSERM Cochin Institute in Paris have shown that a previously under-researched region of the genome also plays a crucial role in the development of this disease.

Chronic inflammatory bowel diseases - 25/09/2024

Proinflammatory regulatory T lymphocytes as a therapeutic target in Crohn's disease

Chronic inflammatory bowel diseases are very stressful for those affected and increase the risk of bowel cancer. PD Dr. Robyn Laura Kosinsky from the Bosch Health Campus in Stuttgart, together with researchers from the USA, identified disfunctional regulatory T cells as important drivers of inflammation in Crohn's disease. They also found that with the help of an epigenetically active drug, it was possible to restore the cells’ original…

Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…

The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.

Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year. A team of KIT researchers has now identified a new cell type in blood vessels responsible for vascular growth. This discovery may allow for novel therapeutic strategies to treat ischemic cardiovascular diseases, i.e. diseases that are caused by reduced or absent blood flow.

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.

CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demon­strated relevance in glioblastoma. A first data readout is expected in the second half of 2024.

Konstanz researchers discover the function of a previously unexplored protein: In three characteristic steps, "C12orf29" links the ends of RNA strands. Proteins that perform this kind of RNA ligation were previously unknown in humans. The results of the study suggest that it is important for RNA repair during cellular stress.

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK.

Researchers of the University of Freiburg introduce biosensor for the nucleic acid amplification-free detection of SARS-CoV-2 RNA.

Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…

Hummingbird Diagnostics GmbH - 22/09/2022

The great potential of blood-based microRNA analyses

"The early bird catches the worm", is an apt description of what motivates Hummingbird Diagnostics GmbH from Heidelberg. The medium-sized biotechnology company analyses special biomarkers in blood, so-called microRNAs, in order to diagnose diseases at an early stage and to be able to make forecasts about the course of the disease and the success of therapy.

With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.

Mitochondria are the power plants of cells, and they contain their own genetic material and RNA molecules. Scientists from the German Cancer Research Center (DKFZ) have now discovered that certain modifications in mitochondrial RNA boost the invasive spread of cancer cells by supporting protein synthesis in mitochondria.

The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.